Page 2 of 19 · 454 questions tagged vendor-vetting.
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I can parse the result. I am less sure what it licenses me to conclude. I have…
What I have: a GLP-1 receptor agonist · purity figure. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
For reference: FGP · cagrilintide. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have photographed the…
This is my second independent submission on material from the same supplier. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware…
What I am working with: MKM · survodutide. An unexpected observation, and I would like a differential rather than reassurance. The conditions were within what I…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I want a method I can write down and repeat, not a rule of thumb. I would…
Conditions: WXT · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the primary…
Concretely: 95.2% · liraglutide · ERP. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
For reference: 97.9% · ecnoglutide · JEEP. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I have the document in front of me and I can read the numbers. What I…
The case in front of me: 98.8% · oral semaglutide · QSC. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I…
What I have: SWB · Qingdao Sigma Chemical. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Conditions: VendorInvestigate · Zhuhai Kerui Biotechnology. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
I am comparing a supplier certificate against an independent result on the same lot. I have read the primary source rather than the summary, which has left me with…
Details up front: 99.4% · retatrutide · GL Biochem. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. Somebody stated this to me confidently and I would like to check it before…
The method section is present, which is unusual enough that I want to make use of it. This is a procedural question rather than a theoretical one, and I would like…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I would like to understand the steps well enough to explain them to someone…
Details up front: 98.8% · orforglipron · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum…
The case in front of me: lot-specific certificate · WWB. I have read the primary source rather than the summary, which has left me with more questions. I understand…
The method section is present, which is unusual enough that I want to make use of it. This has the shape of a fact but I cannot find its origin. What I found instead…
Concretely: 97.9% · tirzepatide · ERP. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
Stated plainly: QST · Zhuhai Kerui Biotechnology. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that,…
The specifics, since they change the answer: 96.8% · ecnoglutide · WWB. I am at the decision point and I would rather think it through than improvise. I would rather…